Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report issued on Thursday. The brokerage issued a sell rating on the stock.

Separately, Roth Mkm reiterated a buy rating and set a $40.00 price target on shares of Moleculin Biotech in a research note on Friday, April 12th.

Moleculin Biotech Stock Up 14.1 %

Shares of MBRX stock opened at $2.59 on Thursday. The stock’s 50-day moving average is $3.91 and its two-hundred day moving average is $5.61. Moleculin Biotech has a 1 year low of $2.12 and a 1 year high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Friday, May 10th. The company reported ($2.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $1.57. Research analysts forecast that Moleculin Biotech will post -6.78 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC acquired a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned about 9.60% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.